Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous TCR-engineered T cells IMA201

A preparation of autologous T lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for an as of yet not identified tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T cells IMA201 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ACTengine IMA201
autologous T-cell receptor-engineered T cells IMA201
IMA201 autologous T lymphocytes
IMA201 T cells
Code name:IMA 201
IMA-201
IMA201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search